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ABSTRACT
The study aimed to investigate the efficacy of intravenous optic neuritis 
treatment trial (ONTT) regiment on the treatment of patients with acute 
retrobulbar neuritis. This was a cross sectional study using medical records 
data of patients diagnosed with unilateral or bilateral retrobulbar neuritis 
by normal funduscopic findings and typical optic neuritis perimetry results 
within 14 days of onset from the Neuro-ophthalmology Clinic, Department 
of Ophthalmology, Dr. Sardjito General Hospital, Yogyakarta from January 
to December 2015. Medical records data of patients who received 1000 mg 
methylprednisolone IV per day for 3 days followed by 11 days 1 mg/kg body 
weight oral prednisolone were reviewed. Visual acuity (VA) at onset, final 
VA at time of follow up, delta VA improvement and time of follow up were 
included in the analyses.  Twenty data of patients aged 33.95±8.07 years with 
VA at onset of 1.96±0.81 (~  1  m CF) were analyzed in this study. Significantly 
improvement in final VA after treatment to be 1.39±1.12 (~ 5 m CF) was 
reported (p=0.001). The VA at onset was a predictive factor for final VA (p 
<0.001). Every 1.17 increase of final VA for every one-point decreased VA at 
onset (p<0.001). Time follow up showed to be trend (p=0.059), however, age 
and sex were not a predictive factor of final VA (p>0.05). In conclusion, there 
is VA improvement after the treatment of ONTT regiment. The VA at onset 
is a predictive factor of final VA on patients with acute retrobulbar neuritis.
ABSTRAK
Penelitian ini bertujuan mengkaji efektivitas regimen optic neuritis 
treatment trial (ONTT) intravena pada pengobatan pasien dengan neuritis 
retrobulbar fase akut. Penelitian potong lintang ini menggunakan rekam 
medis pasien yang didiagnosis neuritis retrobulbar unilateral atau bilateral 
dengan temuan funduskopi normal dan hasil perimetri neuritis optik yang 
khas dalam waktu 14 hari setelah onset dari Klinik Neuro-oftalmologi, 
Departemen Oftalmologi, Rumah Sakit Umum Pusat Dr. Sardjito, Yogyakarta 
dari Januari-Desember 2015. Data rekam medis pasien yang menerima 1000 
mg metilprednisolon IV per hari selama 3 hari diikuti oleh prednisolon oral 
selama 11 hari dengan dosis 1 mg/kg berat badan dianalisis. Ketajaman 
visual (VA) saat onset, VA akhir saat tindak lanjut, peningkatan VA, dan 
waktu tindak lanjut dianalisis. Sebanyak 20 data pasien berumur 33,95 ±8,07 
tahun dengan VA saat onset 1,96 ±0,81 (~ 1 m CF) dianalisis dalam penelitian 
ini. Perbaikan VA akhir menjadi 1,39±1,12 (~ 5 m CF) dilaporkan (p=0,001). 
Ketajaman visual saat onset merupakan factor predictor VA akhir (p<0,001). 
Setiap peningkatan VA akhir sebesar 1,17 menurunkan satu poin VA saat 
onset (p<0.001). Waktu tindak lanjut cenderung menjadi factor prediktor 
(p=0,059), namun demikian usia, jenis kelamin bukan factor predictor VA 
akhir (p>0,05). Dapat disimpulkan, terdapat peningkatan VA pasien setelah 
pengobatan regimen ONTT. Ketajaman visual saat onset merupakan faktor 
prediktor VA akhir pada pasien dengan neuritis retrobulbar akut. 
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INTRODUCTION
Optic neuritis is defined as an 
inflammation affecting the optic nerve. 
It is a frequent cause of acute optic 
nerve injury in children and adults.1 
Optic neuritis commonly related to 
demyelinating optic neuritis, which 
ultimately evolve into multiple sclerosis 
(MS). The other form of optic neuritis is 
severe immune-mediated demyelinating 
disease that injured the optic nerves as 
part of neuromyelitis optica spectrum 
disease (NMOSD).2,3 The estimated 
lifetime prevalence of optic neuritis was 
0.6/1000, and the incidence that adjusted 
to the age and sex was 1–5/100000.4,5 
Several studies reported that young 
female Caucasian frequently suffered 
from optic neuritis with the mean age 
of onset is 31–32 years.6-8 The female 
predominance also mentioned in study 
from Asia, with the mean age of 40 years 
old.9
According to the involved location, 
optic neuritis can be differed as a 
retrobulbar neuritis (most of cases) 
that appeared with normal optic disc; 
papillitis, which appeared to have a 
swollen disc; perineuritis, in which 
optic nerve sheath was involved 
with normal or swollen optic disc; 
and  neuroretinitis with prominent 
macular star sign and swollen optic 
disc.10,11 The MS was predominantly 
associated with retrobulbar neuritis and 
papillitis. Meanwhile, the perineuritis 
and neuroretinitis were commonly 
involved in infectious or inflammatory 
pathologies.11,12
Retrobulbar neuritis is an 
inflammation affecting the optic nerve 
behind the eyeball characterized by a 
sudden onset of unilateral or bilateral 
visual loss with normal disc appearance. 
Most of the case of retrobulbar neuritis 
are idiopathic in nature, but it could be 
associated with demyelinating lesions 
(multiple sclerosis). Other less common 
etiologies include infectious and para-
infectious causes and inflammatory 
responses.11 The optic neuritis treatment 
trial (ONTT), was the first major study 
that found that patients treated with 
intravenous corticosteroids had faster 
recovery of vision but that visual 
recovery in patients treated with an 
oral placebo was as good after 1 year of 
follow-up as visual recovery in patients 
treated with either intravenous or 
oral corticosteroids.13 The aim of this 
study was to investigate the efficacy of 




This is a retrospective, cross-
sectional study that approved by 
the Institutional Review Board in 
accordance with the Declaration  of 
Helsinki  and was  approved by the 
Medical and Health Research Ethic 
Committee, Faculty of Medicine, Public 
Health and Nursing, Universitas Gadjah 
Mada / Dr. Sardjito General Hospital, 
Yogyakarta (KE/FK/0749/EC/2017). The 
data from medical records of patients 
diagnosed with unilateral or bilateral 
retrobulbar neuritis from the Neuro-
ophthalmology Clinic, Department of 
and Ophthalmology, Dr. Sardjito General 
Hospital, Yogyakarta from January to 
December 2015 were reviewed. The data 
were then derived from the patients who 
diagnosed with unilateral and bilateral 
retrobulbar neuritis.
Protocol of study
Diagnosis of retrobulbar neuritis 
was based on clinical symptom sudden 
visual loss with normal funduscopy 
findings and typical optic neuritis 
perimetry results within 14 days of 
onset. All the patients received 1000 mg 
methylprednisolone IV per day for 3 
days followed by 11 days 1 mg/kg body 
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weight oral prednisolone. Demographic 
data including gender and age of onset 
were recorded. The best corrected visual 
acuity (BCVA) was examined by Snellen 
chart and converted into logarithm of the 
minimal angle of resolution (LogMAR) 
units for statistical analysis. Visual acuity 
(VA) at onset, final VA at time of follow 
up, delta VA improvement and time of 
follow up were included in the analyses. 
Patients with age less than 18 years old 
were excluded.
Statistical analysis
Statistical analyses were 
performed using IBM SPSS Statistics for 
Windows, version 22 (IBM Corp., Armonk, 
N.Y., USA). Predictive factors associated 
with final VA were analyzed using ANOVA 
regression analysis. p-values < 0.05 were 
considered statistically significant.
RESULTS
Twenty patients were included in this 
study. Their mean age was 33.95 ± 8.07 
years (range 21-49 years). Eleven (55%) 
patients were female. The mean time 
of follow up was 0.8750 ± 0.59 months. 
Visual acuity at onset ranged from 20/32 
to light perceptionwith mean initial VA 
was 1.96 ± 0.81 (~ 1 m CF). The predictive 
factors for treatment results are shown 
in TABLE 1. Significantly improvement 
in final VA post therapy to be 1.39±1.12 
(~ 5 m CF) was reported (p=0.001). The 
VA at onset was founds as a predictive 
factor for final VA (p <0.001), while age 
and sex were not a predictive factor of 
final VA post ONTT (p> 0.05). It was also 
reported that in every 1.17 increase of 
final VA was associated with 1-point 
decrease of VA at onset. There was no 
association between time of follow up 
with final VA, but time of follow up were 
shown trend (p=0.059). Thus, VA at the 
onset of acute retrobulbar neuritis was 
a strong predictive factor that important 
to determine the prognosis of VA after 
ONTT.
TABLE 1. Predictive factors for treatment results
Variables Value p PR 95% CI
Sex [n (%)]
•	Male 9 (45)
0.549 0.314 -0.766 – 1.395
•	Female 11 (55)
Age (mean ± SD) 33.95±8.07 0.974 0.001 -0.068 – 0.070
VA at onset (mean ± SD) 1.96±0.81 <0.001* 1.117 0.707 – 1.527
Time of follow up (mean ± SD) 0.8750±0.59 0.059 -0.815 -1.663 – 0.034
PR: Prevalence Ratio
DISCUSSION
This study identified that VA at onset 
was the only factor associated with 
final VA. Every 1.17 increase of final VA 
was associated with 1-point decrease 
of VA at onset. This finding showed the 
efficacy of the ONTT regiment in acute 
retrobulbar neuritis. Previous study 
conducted by Sheti et al.,14 to evaluate the 
efficacy and safety profile of intravenous 
dexamethasone showed that the 
intravenous pulse dexamethasone led 
to rapid recovery of vision in acute optic 
neuritis, without any serious side effects. 
However, another study reported that, 
ONTT indeed proven to be effective in 
accelerate the visual recovery in acute 
optic neuritis, but may not affect the 
final VA.15 This might happen in patient 
with the worst VA at the onset of optic 
neuritis. Another study conducted by 
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Menon et al.,16 reported that intravenous 
dexamethasone to be as effective as mega-
dose intravenous methylprednisolone 
therapy recommended  by the ONTT 
study, with the added advantage of 
being easier to administer and less 
costly (costing one sixth of injection 
methylprednisolone).
In some cases, the benefit of 
corticosteroids treatment might 
relatively subtle when it is present.17 
Several studies reported no serious 
adverse effects were found during 
ONTT.18-20 Approximately 50% of patients 
with ONTT were reported to experience 
insomnia.21 Concordantly, other studies 
also reported several adverse effects, 
such as hyperglycemia, hyperlipidemia, 
headache, weight gain, facial flushing, 
and fever.21,22 Because of this adverse 
effects, the clinician should also consider 
the adverse effect of corticosteroids 
before delivering ONTT.
We also compared the demographic 
data and predictive factors of ONTT 
treatment results. The mean age of onset 
was 33.95 ± 8.07 years. This finding 
was similar to other study reported by 
Zhou et al.23 (mean 34.6 years, range 
18-55 years) and Hansapinyoand 
Vivattanaseth,24 (mean 39.1 years, range 
18-73). The majority of the patients in 
this study were female (55%). However, 
sex was not predictive factor of final VA 
(p= 0.549). This finding was different 
with the study conducted by Hansapinyo 
and Vivattanaseth24 which showed that 
female-male ratio was higher in patients 
with NMOSD.
The retrospective design of this 
study, incomplete and varied data 
documentation, and small sample size 
were limitations in this study. Future 
prospective studies to determine the 
appropriate diagnostic and treatment 
protocol of retrobulbar neuritis should 
be performed by using experimental 
study design.
CONCLUSION
There isVA improvement after the 
treatment of ONTT regiment. The VA at 
onset is a predictive factor of final VAon 
patients with acute retrobulbar neuritis.
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